Squaric acid derivatives as inhibitors of the nicotinamide

Abstract

The present application discloses novel squaric acid derivatives of the formula A: from —C(═O)—, —S(═O)—, —C(═S)— and —P(═O)(R)—; B: -, —O—, —NR— and —C(═O)—NR—; D: -, —O—, —CRR— and —NR; m=0-12; n=0-12; m+n=1-20; p=0-2; R: heteroaryl, aryl; R: H, C-alkyl, C-cycloalkyl, —[CHCHO]—(C-alkyl), C-alkenyl, aryl, heterocyclyl, heteroaryl; R: C-alkyl, C-cycloalkyl, —[CHCHO]—(C-alkyl), C-alkenyl, aryl, heterocyclyl, heteroaryl; or Rand R: N-containing heterocyclic/heteroaromatic ring; Rand R*: H, C-alkyl, C-alkenyl; and pharmaceutically acceptable salts and prodrugs thereof, and their use in the treatment of diseases/conditions caused by an elevated level of NAMPRT (inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and CPOD, osteoarthritis, osteoporosis and fibrotic diseases; dermatosis; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and viral infections, adult respiratory distress syndrome, ataxia telengiectasia).